Lorus Virulizin pancreatic cancer data
This article was originally published in Pharmaceutical Approvals Monthly
Lorus Therapeutics believes its immunotherapy Virulizin could benefit a subgroup of pancreatic cancer patients with ECOG performance status of 0 or 1, the firm says Oct. 18. The Toronto biotech found, however, that its Phase III trial did not show statistical significance for median overall survival in chemo-naïve patients receiving Virulizin plus gemcitabine compared to placebo plus gemcitabine. "For the efficacy evaluable population, the study showed that the addition of Virulizin to gemcitabine resulted in a median [OS] of 6.8 months and a one-year survival rate of 27.2%, compared to 6.0 months and 16.8% for placebo plus gemcitabine," Lorus said. In ECOG PS 0/1 patients, "the result approached statistical significance with a p-value of 0.063"...
You may also be interested in...
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.